• Citius Oncology board resolutions dated May 5 set up stock issuance tied to a new Loan Agreement, later ratified by majority written consent on May 22.
• Written consent cleared share issuance for lenders’ conversion option on up to USD 4 million loan principal at USD 1.08 per share.
• Consent also authorized stock issuance on exercise of lender warrants, sized off USD 1 million value and 10% of funded later tranches at USD 0.9.
• Stockholder action approved issuance on May 2026 inducement warrants for 25,555,556 shares at USD 0.9, placement-agent warrants for 894,444 shares at USD 1.13.
• December 2025 warrants were amended to cut the exercise price to USD 0.9, extend term to five years, and require stockholder approval before exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-062911), on May 29, 2026, and is solely responsible for the information contained therein.